Eduardo Tolosa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Eduardo Tolosa has a total of 214 co-authors. Here are the top co-authors by number of shared publications:
Francesc Valldeoriola
Neurology Department, Hospital Clinic de Barcelona, Barcelona, Spain
11 shared publicationsYaroslau Compta
Hospital Clínic de Barcelona Movement Disorders Unit, Neurology Service Barcelona Catalonia Spain
9 shared publicationsDolores Vilas
Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut de Neurociències Hospital Clínic, Universitat de Barcelona, Catalonia, Spain
8 shared publicationsCarles Gaig
Neurology Service, Hospital Clínic de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer, Universidad de Barcelona, Barcelona, Spain
7 shared publicationsMaria José Martí
Parkinson's Disease and Movement Disorders Unit Institut Clínic de Neurociències Hospital Clinic de Barcelona Barcelona Spain
6 shared publicationsMiquel Aguilar
Hospital Universitari Mutua de Terrasa Neurology Service Barcelona Catalonia Spain
5 shared publications
Latest Publications
- Open Access
- 8 February 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (3)
Blocking IL-6 signaling prevents astrocyte-induced neurodegeneration in an iPSC-based model of Parkinson’s disease
Parkinson’s disease (PD) is a neurodegenerative disease associated with progressive death of midbrain dopamine (DAn) neurons in the substantia nigra (SN). Since it has been proposed that patients with PD exhibit an overall proinflammatory state, and since astrocytes are key mediators of the inflammation response in the brain, here we sought to address whether astrocyte-mediated inflammatory signaling could contribute to PD neuropathology. For this purpose, we generated astrocytes from induced pluripotent stem cells (iPSCs) representing patients with PD and healthy controls. Transcriptomic analyses identified a unique inflammatory gene expression signature in PD astrocytes compared with controls. In particular, the proinflammatory cytokine IL-6 was found to be highly expressed and released by PD astrocytes and was found to induce toxicity in DAn. Mechanistically, neuronal cell death was mediated by IL-6 receptor (IL-6R) expressed in human PD neurons, leading to downstream activation of STAT3. Blockage of IL-6R by the addition of the FDA-approved anti–IL-6R antibody, Tocilizumab, prevented PD neuronal death. SN neurons overexpressing IL-6R and reactive astrocytes expressing IL-6 were detected in postmortem brain tissue of patients at early stages of PD. Our findings highlight the potential role of astrocyte-mediated inflammatory signaling in neuronal loss in PD and pave the way for the design of future therapeutics.
- 8 February 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (3)
Open AccessBlocking IL-6 signaling prevents astrocyte-induced neurodegeneration in an iPSC-based model of Parkinson’s disease
Parkinson’s disease (PD) is a neurodegenerative disease associated with progressive death of midbrain dopamine (DAn) neurons in the substantia nigra (SN). Since it has been proposed that patients with PD exhibit an overall proinflammatory state, and since astrocytes are key mediators of the inflammation response in the brain, here we sought to address whether astrocyte-mediated inflammatory signaling could contribute to PD neuropathology. For this purpose, we generated astrocytes from induced pluripotent stem cells (iPSCs) representing patients with PD and healthy controls. Transcriptomic analyses identified a unique inflammatory gene expression signature in PD astrocytes compared with controls. In particular, the proinflammatory cytokine IL-6 was found to be highly expressed and released by PD astrocytes and was found to induce toxicity in DAn. Mechanistically, neuronal cell death was mediated by IL-6 receptor (IL-6R) expressed in human PD neurons, leading to downstream activation of STAT3. Blockage of IL-6R by the addition of the FDA-approved anti–IL-6R antibody, Tocilizumab, prevented PD neuronal death. SN neurons overexpressing IL-6R and reactive astrocytes expressing IL-6 were detected in postmortem brain tissue of patients at early stages of PD. Our findings highlight the potential role of astrocyte-mediated inflammatory signaling in neuronal loss in PD and pave the way for the design of future therapeutics.
- Open Access
- 19 August 2019
- Published by BMJ in Practical Neurology
- Vol. 20 (1) , 15-25
Emergencies and critical issues in Parkinson’s disease
Complications from Parkinson’s disease may develop over the disease course, sometimes unexpectedly, and require prompt or even urgent medical intervention. The most common are associated with aggravation of motor symptoms; serious non-motor complications, such as psychosis, orthostatic hypotension or sleep attacks, also occur. Here we review such complications, their clinical presentation, precipitating factors and management, including those related to using device-aided therapies. Early recognition and prompt attention to these critical situations is challenging, even for the Parkinson’s disease specialist, but is essential to prevent serious problems.
- 19 August 2019
- Published by BMJ in Practical Neurology
- Vol. 20 (1) , 15-25
Open AccessEmergencies and critical issues in Parkinson’s disease
Complications from Parkinson’s disease may develop over the disease course, sometimes unexpectedly, and require prompt or even urgent medical intervention. The most common are associated with aggravation of motor symptoms; serious non-motor complications, such as psychosis, orthostatic hypotension or sleep attacks, also occur. Here we review such complications, their clinical presentation, precipitating factors and management, including those related to using device-aided therapies. Early recognition and prompt attention to these critical situations is challenging, even for the Parkinson’s disease specialist, but is essential to prevent serious problems.
- Open Access
- 9 May 2019
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 6 (6) , 1024-1032
α‐synuclein RT‐QuIC in cerebrospinal fluid of LRRK2‐linked Parkinson's disease
Background: Leucine‐rich kinase 2 (LRRK2)‐linked Parkinson's disease (PD) is clinically indistinguishable from idiopathic PD (IPD). A pleiotropic neuropathology has been recognized but the majority of studies in LRRK2 p.G2019S patients reveal Lewy‐type synucleinopathy as its principal histological substrate. To date no in vivo biomarkers of synucleinopathy have been found in LRRK2 mutation carriers.Objectives: We used real‐time quaking‐induced conversion (RT‐QuIC) technique to assess the presence of alpha‐synuclein (a‐syn) aggregates in cerebrospinal fluid (CSF) of LRRK2 p.G2019S carriers.Methods: CSF samples of 51 subjects were analyzed: 15 LRRK2 p.G2019S PD, 10 IPD, 16 LRRK2 p.G2019S nonmanifesting carriers (NMC) and 10 healthy controls. The presence of parkinsonism and prodromal symptoms was assessed in all study subjects.Results: Forty percent (n = 6) LRRK2‐PD, and 18.8% (n = 3) LRRK2‐NMC had a positive a‐syn RT‐QuIC response. RT‐QuIC detected IPD with 90% sensitivity and 80% specificity. No clinical differences were detected between LRRK2‐PD patients with positive and negative RT‐QuIC. A positive RT‐QuIC result in LRRK2‐NMC occurred in a higher proportion of subjects meeting the Movement Disorder Society research criteria for prodromal PD.Interpretation: RT‐QuIC detects a‐syn aggregation in CSF in a significant number of patients with LRRK2‐PD, but less frequently than in IPD. A small percentage of LRRK2‐NMC tested also positive. If appropriately validated in long‐term studies with large number of mutation carriers, and hopefully, postmortem or in vivo confirmation of histopathology, RT‐QuIC could contribute to the selection of candidates to receive disease modifying drugs, in particular treatments targeting a‐syn deposition.
- 9 May 2019
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 6 (6) , 1024-1032
Open Accessα‐synuclein RT‐QuIC in cerebrospinal fluid of LRRK2‐linked Parkinson's disease
Background: Leucine‐rich kinase 2 (LRRK2)‐linked Parkinson's disease (PD) is clinically indistinguishable from idiopathic PD (IPD). A pleiotropic neuropathology has been recognized but the majority of studies in LRRK2 p.G2019S patients reveal Lewy‐type synucleinopathy as its principal histological substrate. To date no in vivo biomarkers of synucleinopathy have been found in LRRK2 mutation carriers.Objectives: We used real‐time quaking‐induced conversion (RT‐QuIC) technique to assess the presence of alpha‐synuclein (a‐syn) aggregates in cerebrospinal fluid (CSF) of LRRK2 p.G2019S carriers.Methods: CSF samples of 51 subjects were analyzed: 15 LRRK2 p.G2019S PD, 10 IPD, 16 LRRK2 p.G2019S nonmanifesting carriers (NMC) and 10 healthy controls. The presence of parkinsonism and prodromal symptoms was assessed in all study subjects.Results: Forty percent (n = 6) LRRK2‐PD, and 18.8% (n = 3) LRRK2‐NMC had a positive a‐syn RT‐QuIC response. RT‐QuIC detected IPD with 90% sensitivity and 80% specificity. No clinical differences were detected between LRRK2‐PD patients with positive and negative RT‐QuIC. A positive RT‐QuIC result in LRRK2‐NMC occurred in a higher proportion of subjects meeting the Movement Disorder Society research criteria for prodromal PD.Interpretation: RT‐QuIC detects a‐syn aggregation in CSF in a significant number of patients with LRRK2‐PD, but less frequently than in IPD. A small percentage of LRRK2‐NMC tested also positive. If appropriately validated in long‐term studies with large number of mutation carriers, and hopefully, postmortem or in vivo confirmation of histopathology, RT‐QuIC could contribute to the selection of candidates to receive disease modifying drugs, in particular treatments targeting a‐syn deposition.
- 9 November 2017
- Published by Wiley in Movement Disorders
- Vol. 33 (2) , 335-338
Clinical and neuropathological features of progressive supranuclear palsy in Leucine rich repeat kinase (LRRK2) G2019S mutation carriers
- 9 November 2017
- Published by Wiley in Movement Disorders
- Vol. 33 (2) , 335-338
Clinical and neuropathological features of progressive supranuclear palsy in Leucine rich repeat kinase (LRRK2) G2019S mutation carriers
- Open Access
- 8 August 2017
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 7 (3) , 459-463
A Novel p.Glu298Lys Mutation in the ACMSD Gene in Sporadic Parkinson’s Disease
Common genetic variability in the ACMSD gene has been associated with increased risk for Parkinson’s disease (PD) but ACMSD mutations in clinical cases of PD have so far not been described. We report a 74-year-old man with sporadic PD who developed t
- 8 August 2017
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 7 (3) , 459-463
Open AccessA Novel p.Glu298Lys Mutation in the ACMSD Gene in Sporadic Parkinson’s Disease
Common genetic variability in the ACMSD gene has been associated with increased risk for Parkinson’s disease (PD) but ACMSD mutations in clinical cases of PD have so far not been described. We report a 74-year-old man with sporadic PD who developed t
- 28 March 2017
- Published by Wiley in Movement Disorders
- Vol. 32 (5) , 726-738
The prodromal phase of leucine‐rich repeat kinase 2–associated Parkinson disease: Clinical and imaging Studies
Background: Asymptomatic, nonmanifesting carriers of leucine‐rich repeat kinase 2 mutations are at increased risk of developing PD. Clinical and neuroimaging features may be associated with gene carriage and/or may demarcate individuals at greater risk for phenoconversion to PD.Objectives: To investigate clinical and dopamine transporter single‐photon emission computed tomography imaging characteristics of leucine‐rich repeat kinase 2 asymptomatic carriers.Methods: A total of 342 carriers' and 259 noncarriers' relatives of G2019S leucine‐rich repeat kinase 2/PD patients and 39 carriers' and 31 noncarriers' relatives of R1441G leucine‐rich repeat kinase 2/PD patients were evaluated. Motor and nonmotor symptoms were assessed using specific scales and questionnaires. Neuroimaging quantitative data were obtained in 81 carriers and compared with 41 noncarriers.Results: G2019S carriers scored higher in motor scores and had lower radioligand uptake compared to noncarriers, but no differences in nonmotor symptoms scores were observed. R1441G carriers scored higher in motor scores, had lower radioligand uptake, and had higher scores in depression, dysautonomia, and Rapid Eye Movements Sleep Behavior Disorder Screening Questionnaire scores, but had better cognition scores than noncarriers. Among G2019S carriers, a group with “mild motor signs” was identified, and was significantly older, with worse olfaction and lower radioligand uptake.Conclusions: G2019S and R1441G carriers differ from their noncarriers' relatives in higher motor scores and slightly lower radioligand uptake. Nonmotor symptoms were mild, and different nonmotor profiles were observed in G2019S carriers compared to R1441G carriers. A group of G2019S carriers with known prodromal features was identified. Longitudinal studies are required to determine whether such individuals are at short‐term risk of developing overt parkinsonism. © 2017 International Parkinson and Movement Disorder Society
- 28 March 2017
- Published by Wiley in Movement Disorders
- Vol. 32 (5) , 726-738
The prodromal phase of leucine‐rich repeat kinase 2–associated Parkinson disease: Clinical and imaging Studies
Background: Asymptomatic, nonmanifesting carriers of leucine‐rich repeat kinase 2 mutations are at increased risk of developing PD. Clinical and neuroimaging features may be associated with gene carriage and/or may demarcate individuals at greater risk for phenoconversion to PD.Objectives: To investigate clinical and dopamine transporter single‐photon emission computed tomography imaging characteristics of leucine‐rich repeat kinase 2 asymptomatic carriers.Methods: A total of 342 carriers' and 259 noncarriers' relatives of G2019S leucine‐rich repeat kinase 2/PD patients and 39 carriers' and 31 noncarriers' relatives of R1441G leucine‐rich repeat kinase 2/PD patients were evaluated. Motor and nonmotor symptoms were assessed using specific scales and questionnaires. Neuroimaging quantitative data were obtained in 81 carriers and compared with 41 noncarriers.Results: G2019S carriers scored higher in motor scores and had lower radioligand uptake compared to noncarriers, but no differences in nonmotor symptoms scores were observed. R1441G carriers scored higher in motor scores, had lower radioligand uptake, and had higher scores in depression, dysautonomia, and Rapid Eye Movements Sleep Behavior Disorder Screening Questionnaire scores, but had better cognition scores than noncarriers. Among G2019S carriers, a group with “mild motor signs” was identified, and was significantly older, with worse olfaction and lower radioligand uptake.Conclusions: G2019S and R1441G carriers differ from their noncarriers' relatives in higher motor scores and slightly lower radioligand uptake. Nonmotor symptoms were mild, and different nonmotor profiles were observed in G2019S carriers compared to R1441G carriers. A group of G2019S carriers with known prodromal features was identified. Longitudinal studies are required to determine whether such individuals are at short‐term risk of developing overt parkinsonism. © 2017 International Parkinson and Movement Disorder Society
- 21 September 2016
- Published by Wiley in Movement Disorders
- Vol. 31 (12) , 1820-1828
Nigral and striatal connectivity alterations in asymptomatic LRRK2 mutation carriers: A magnetic resonance imaging study
Background: The study of functional connectivity by means of magnetic resonance imaging (MRI) in asymptomatic LRRK2 mutation carriers could contribute to the characterization of the prediagnostic phase of LRRK2‐associated Parkinson's disease (PD). The objective of this study was to characterize MRI functional patterns during the resting state in asymptomatic LRRK2 mutation carriers.Methods: We acquired structural and functional MRI data of 18 asymptomatic LRRK2 mutation carriers and 18 asymptomatic LRRK2 mutation noncarriers, all first‐degree relatives of LRRK2‐PD patients. Starting from resting‐state data, we analyzed the functional connectivity of the striatocortical and the nigrocortical circuitry. Structural brain data were analyzed by voxel‐based morphometry, cortical thickness, and volumetric measures.Results: Asymptomatic LRRK2 mutation carriers had functional connectivity reductions between the caudal motor part of the left striatum and the ipsilateral precuneus and superior parietal lobe. Connectivity in these regions correlated with subcortical gray‐matter volumes in mutation carriers. Asymptomatic carriers also showed increased connectivity between the right substantia nigra and bilateral occipital cortical regions (occipital pole and cuneus bilaterally and right lateral occipital cortex). No intergroup differences in structural MRI measures were found. In LRRK2 mutation carriers, age and functional connectivity correlated negatively with striatal volumes. Additional analyses including only subjects with the G2019S mutation revealed similar findings.Conclusions: Asymptomatic LRRK2 mutation carriers showed functional connectivity changes in striatocortical and nigrocortical circuits compared with noncarriers. These findings support the concept that altered brain connectivity precedes the onset of classical motor features in a genetic form of PD. © 2016 International Parkinson and Movement Disorder Society
- 21 September 2016
- Published by Wiley in Movement Disorders
- Vol. 31 (12) , 1820-1828
Nigral and striatal connectivity alterations in asymptomatic LRRK2 mutation carriers: A magnetic resonance imaging study
Background: The study of functional connectivity by means of magnetic resonance imaging (MRI) in asymptomatic LRRK2 mutation carriers could contribute to the characterization of the prediagnostic phase of LRRK2‐associated Parkinson's disease (PD). The objective of this study was to characterize MRI functional patterns during the resting state in asymptomatic LRRK2 mutation carriers.Methods: We acquired structural and functional MRI data of 18 asymptomatic LRRK2 mutation carriers and 18 asymptomatic LRRK2 mutation noncarriers, all first‐degree relatives of LRRK2‐PD patients. Starting from resting‐state data, we analyzed the functional connectivity of the striatocortical and the nigrocortical circuitry. Structural brain data were analyzed by voxel‐based morphometry, cortical thickness, and volumetric measures.Results: Asymptomatic LRRK2 mutation carriers had functional connectivity reductions between the caudal motor part of the left striatum and the ipsilateral precuneus and superior parietal lobe. Connectivity in these regions correlated with subcortical gray‐matter volumes in mutation carriers. Asymptomatic carriers also showed increased connectivity between the right substantia nigra and bilateral occipital cortical regions (occipital pole and cuneus bilaterally and right lateral occipital cortex). No intergroup differences in structural MRI measures were found. In LRRK2 mutation carriers, age and functional connectivity correlated negatively with striatal volumes. Additional analyses including only subjects with the G2019S mutation revealed similar findings.Conclusions: Asymptomatic LRRK2 mutation carriers showed functional connectivity changes in striatocortical and nigrocortical circuits compared with noncarriers. These findings support the concept that altered brain connectivity precedes the onset of classical motor features in a genetic form of PD. © 2016 International Parkinson and Movement Disorder Society
- 1 June 2016
- Published by Elsevier in The Lancet Neurology
- Vol. 15 (7) , 708-718
Assessment of α-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study
- 1 June 2016
- Published by Elsevier in The Lancet Neurology
- Vol. 15 (7) , 708-718
Assessment of α-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study
- 1 May 2016
- Published by Elsevier in The Lancet Neurology
- Vol. 15 (6) , 637-648
Challenges of modifying disease progression in prediagnostic Parkinson's disease
- 1 May 2016
- Published by Elsevier in The Lancet Neurology
- Vol. 15 (6) , 637-648
Challenges of modifying disease progression in prediagnostic Parkinson's disease
- 6 April 2016
- Published by Springer Nature in Current Geriatrics Reports
- Vol. 5 (2) , 85-94
Update on the Diagnosis and Management of Progressive Supranuclear Palsy
- 6 April 2016
- Published by Springer Nature in Current Geriatrics Reports
- Vol. 5 (2) , 85-94
Update on the Diagnosis and Management of Progressive Supranuclear Palsy